Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio’s analyst, the global factor VIII deficiency treatment market is anticipated to grow at a steady rate and post a CAGR of close to 6% during the forecast period. The increasing adoption rate of prophylactic drugs will drive the growth prospects for the global factor VIII deficiency treatment market until the end of 2021.
In terms of geography, the Americas accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market for the next four years. Some of the major factors responsible for the market’s growth in the region is the growing number of new product launches and increasing amount of investment in manufacturing and production facilities by various vendors.
The global factor VIII deficiency treatment market is highly competitive and diversified due to the presence of a large number of regional and international vendors across the globe. It has been observed that these vendors in the factor 8 deficiency treatment market are increasingly competing against each other based on factors such as aggressive pricing, novel products such as extended half-life therapies, gene therapy products, and prophylactic drugs.
The global hemophilia A drugs market segment accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market for the next four years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
The prophylaxis segment accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market during the forecasted period. One of the major factors responsible for the market segment's growth is the cost-effectiveness of prophylactic treatment in comparison to on-demand treatment.
Technavio also offers customization on reports based on specific client requirement.
Related reports
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Deficiency overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by type of disease application
PART 09: Market segmentation by type of therapy
PART 10: Market segmentation by type of disease management
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Key vendor analysis
PART 19: Appendix
Tags: hemophilia a, hemophilia treatment, medical devices, diagnostic imaging services, healthcare market analysis, medical devices market share,
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.